Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526923 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
A Phase 1 study of Cystic Fibrosis, sponsored by Spirovant Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT06526923 is a Phase 1 study of Cystic Fibrosis that is actively recruiting participants, run by Spirovant Sciences. The registered enrollment target is 15 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06526923, a Phase 1 study of Cystic Fibrosis, is actively recruiting participants, sponsored by Spirovant Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.
Conditions Studied
Interventions
- COMBINATION_PRODUCT SP-101 and doxorubicin Cohort 1
- COMBINATION_PRODUCT SP-101 and doxorubicin Cohort 2
Study Locations (4)
Kansas
- University of Kansas Medical Center - Kansas City
Massachusetts
- Boston Children's Hospital, Brigham & Women's Hospital - Boston
New York
- Columbia University - New York
Pennsylvania
- Hospital at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526923
The ClinicalTrials.gov registry entry for NCT06526923 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (92% lower). The listed sponsor is Spirovant Sciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which SP-101 and doxorubicin Cohort 1 is the first listed.
NCT06526923 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Kansas, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06526923 about?
NCT06526923 is a clinical study titled "A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)". This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.
What is the current status of trial NCT06526923?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-09-16. Estimated completion is 2026-12-31.
What conditions does trial NCT06526923 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT06526923?
The interventions under investigation include: SP-101 and doxorubicin Cohort 1 (COMBINATION_PRODUCT), SP-101 and doxorubicin Cohort 2 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06526923?
This trial is sponsored by Spirovant Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526923 being conducted?
This trial has 4 study locations across Kansas, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.